ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
Marcus Mall
Abstract
<b>ENaC inhibition with BI 1265162 is a promising strategy to optimise outcomes in patients with CF either eligible, or ineligible, for CFTR modulator therapy. Phase II clinical trials of BI 1265162 must now show this translates into clinical benefit.</b>https://bit.ly/2OQ1IUI
Topics & Concepts
MedicineCystic fibrosisEpithelial sodium channelCancer researchInternal medicineSodiumOrganic chemistryChemistryCystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchInhalation and Respiratory Drug Delivery